Advertisement
Editorial: Which Scott Gottlieb will run the FDA?

Editorial: Which Scott Gottlieb will run the FDA?

By Merrill Goozner  |  April 08, 2017

Dr. Scott Gottlieb is by far the most conflicted person nominated to run the 111-year-old Food and Drug Administration. If the Office of Government Ethics was doing its job, it wouldn't let him near the commissioner's chair for at least a year.

Editorial: A bold proposal for Trumpcare 2.0

Editorial: A bold proposal for Trumpcare 2.0

By Merrill Goozner  |  April 01, 2017

It was notable that so many conservative activists and pundits rushed to abandon the Republican Party's promise to “repeal and replace” Obamacare in the wake of Trumpcare's humiliating defeat in the House of Representatives.

Editorial: Some insurance benefits are essential

Editorial: Some insurance benefits are essential

By Merrill Goozner  |  March 25, 2017

The House of Representatives last week postponed voting to gut Obamacare after new provisions weakening the essential benefits guarantee failed to win support from right-wing Republicans, who are opposed to any form of subsidized health insurance.

Editorial: The medical imperative for data-sharing

Editorial: The medical imperative for data-sharing

By Merrill Goozner  |  February 25, 2017

Bryce Olson, a 47-year-old Intel marketing executive wants to link medical records from across the U.S. and the world into a vast virtual warehouse for research.

Editorial: Give Seema Verma a chance

Editorial: Give Seema Verma a chance

By Merrill Goozner  |  February 18, 2017

Seema Verma, the Indiana consultant who injected personal responsibility requirements and health savings accounts into that state's Medicaid program, deserves a shot at working with other states that want to redesign their programs.

Editorial: 'Right to try' laws could impede medical progress

Editorial: 'Right to try' laws could impede medical progress

By Merrill Goozner  |  February 11, 2017

The Trump administration has thrown its weight behind giving patients the “right to try” experimental drugs outside clinical trials. While such laws purport to offer hope for the dying, they will actually slow medical progress.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print